WHO approves Chinese COVID-19 vaccine for emergency use
United Nations
08 May 2021, 07:21 GMT+10
A COVID-19 vaccine produced in China has been given the green light for global rollout, potentially paving the way for its use in underserved countries, the World Health Organization (WHO) announced on Friday.
The UN agency has approved the Sinopharm vaccine for emergency use, which is a prerequisite for inclusion in the global vaccine solidarity initiative, COVAX.
The vaccine is easy to store, making it suitable for locations with limited resources, and proved 79 per cent effective in clinical trials. The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk , said Dr Mariângela Simao, WHO Assistant-Director General for Access to Health Products.
Chinese vaccine Sinopharm gets emergency approval by WHO 1 minute read
Geneva, May 7 (EFE).- The World Health Organisation approved emergency use of the Covid-19 vaccine made by Chinese company Sinopharm on Friday.
The approval means Sinopharm can be rolled out globally, a WHO statement said.
“The addition of this vaccine has the potential to rapidly accelerate Covid-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products.
Sinopharm has been shown to be up to 79% effective in preventing severe cases of Covid and the symptoms associated with this disease, the chairman of an advisory WHO panel, Alejandro Cravioto, said at a press conference.
COVID-19: WHO approves emergency use of China s Sinopharm COVID-19 vaccine ANI | Updated: May 08, 2021 02:41 IST
Geneva [Switzerland], May 8 (ANI): The World Health Organisation (WHO) on Friday approved the Chinese SinopharmCOVID-19 vaccine for emergency use, paving the way for it to be rolled out globally.
The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG). The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk, said Dr Mariangela Simao, WHO Assistant-Director General for Access to Health Products, in a statement.